Literature DB >> 31090904

Glucocorticoid Activity of Adrenal Steroid Precursors in Untreated Patients With Congenital Adrenal Hyperplasia.

Manon Engels1,2, Karijn J Pijnenburg-Kleizen1, Agustini Utari3,4, Sultana M H Faradz3,4, Sandra Oude-Alink2, Antonius E van Herwaarden2, Paul N Span2,5, Fred C Sweep2, Hedi L Claahsen-van der Grinten1.   

Abstract

CONTEXT AND
OBJECTIVE: We describe the clinical features and biochemical characteristics of a unique population of severely affected untreated patients with congenital adrenal hyperplasia (CAH) from an Indonesian population with proven cortisol deficiency but without clinical signs of cortisol deficiency. We evaluated the in vitro glucocorticoid activity of all relevant adrenal steroid precursors occurring in patients with CAH.
DESIGN: Cross-sectional cohort study and translational research. INTERVENTION/MAIN OUTCOME MEASURES: Adrenal steroid precursor concentrations before and 60 minutes after ACTH administration to 24 untreated patients with CAH (3 to 46 years) with proven cortisol deficiency (<500 nmol/L post-ACTH) measured by liquid chromatography-tandem mass spectrometry were compared with six control patients (Mann-Whitney U test). Glucocorticoid receptor (GR) activation was determined by dual-luciferase assays in human embryonic kidney cells transfected with the GR and exposed to increasing amounts of adrenal steroid precursors for 24 hours.
RESULTS: Blood concentrations of the steroid precursors 11-deoxycortisol (457 nmol/L, P = 0.003), 11-deoxycorticosterone (55 nmol/L, P = 0.003), 17-hydroxyprogesterone (610 nmol/L, P < 0.001), progesterone (29 nmol/L, P < 0.001), and 21-deoxycortisol (73 nmol/L) were strongly elevated compared with control subjects. The GR was activated with comparable potency to cortisol by corticosterone and 21-deoxycortisol or with 4 to 100 times lower potency by 11-hydroxyprogesterone, 11-deoxycortisol, aldosterone, 11-deoxycorticosterone, progesterone, and 17-hydroxyprogesterone.
CONCLUSIONS: We identified strongly elevated adrenal steroid precursor concentrations in blood from untreated patients with CAH and demonstrated glucocorticoid activity of these adrenal precursors in vitro, suggesting a possible role of these precursors in the clinical phenotype of these patients. Further studies are necessary to evaluate the role of these precursors in more detail.
Copyright © 2019 Endocrine Society.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31090904     DOI: 10.1210/jc.2019-00547

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  Face-sparing Congenital Generalized Lipodystrophy Type 1 Associated With Nonclassical Congenital Adrenal Hyperplasia.

Authors:  Sara Costa; Lurdes Sampaio; Ana Berta Sousa; Chao Xing; Anil K Agarwal; Abhimanyu Garg
Journal:  J Clin Endocrinol Metab       Date:  2022-08-18       Impact factor: 6.134

2.  Congenital adrenal hyperplasia in patients with adrenal tumors: a population-based case-control study.

Authors:  F Sahlander; J Patrova; B Mannheimer; J D Lindh; H Falhammar
Journal:  J Endocrinol Invest       Date:  2022-10-21       Impact factor: 5.467

Review 3.  Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management.

Authors:  Hedi L Claahsen-van der Grinten; Phyllis W Speiser; S Faisal Ahmed; Wiebke Arlt; Richard J Auchus; Henrik Falhammar; Christa E Flück; Leonardo Guasti; Angela Huebner; Barbara B M Kortmann; Nils Krone; Deborah P Merke; Walter L Miller; Anna Nordenström; Nicole Reisch; David E Sandberg; Nike M M L Stikkelbroeck; Philippe Touraine; Agustini Utari; Stefan A Wudy; Perrin C White
Journal:  Endocr Rev       Date:  2022-01-12       Impact factor: 19.871

Review 4.  Management challenges and therapeutic advances in congenital adrenal hyperplasia.

Authors:  Ashwini Mallappa; Deborah P Merke
Journal:  Nat Rev Endocrinol       Date:  2022-04-11       Impact factor: 47.564

5.  Quality of Life in Men With Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency.

Authors:  Myrthe J M Verhees; Manon Engels; Paul N Span; Fred C G J Sweep; Antonius E van Herwaarden; Henrik Falhammar; Anna Nordenström; Emma A Webb; Annette Richter-Unruh; Claire Bouvattier; Aude Brac de la Perrière; Wiebke Arlt; Nicole Reisch; Birgit Köhler; Marion Rapp; Nike M M L Stikkelbroeck; Nel Roeleveld; Hedi L Claahsen-van der Grinten
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-19       Impact factor: 5.555

6.  Adrenal Cushing Syndrome Diagnosed During Pregnancy: Successful Medical Management With Metyrapone.

Authors:  Alescia Azzola; Genevieve Eastabrook; Doreen Matsui; Amanda Berberich; Rommel G Tirona; Daryl Gray; Patricia Gallego; Stan Van Uum
Journal:  J Endocr Soc       Date:  2020-11-05

7.  Compliance Issues in Managing 21 Hydroxylase Deficiency and their Short/Long-Term Consequences.

Authors:  Jack Lin; Teck K Khoo; Erin R Voelschow; Zachary J Viets
Journal:  Eur J Case Rep Intern Med       Date:  2021-11-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.